The Thirty-six-Month Immunogenicity Evaluation of Quadrivalent HPV (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in Chinese Female Subjects Aged 9 to 45 Years and Male Subjects Aged 9 to 15 Years
Latest Information Update: 20 Jan 2020
At a glance
- Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary)
- Indications Anal cancer; Cervical cancer; Human papillomavirus infections; Penile cancer
- Focus Pharmacodynamics
- 07 Feb 2018 Results published in the Vaccine.
- 21 Apr 2017 New trial record